Table 1.
Recipient and donor characteristics by baseline tacrolimus exposure and type of MPA treatment
| Baseline tacrolimus exposurea | Baseline MPA | |||||
|---|---|---|---|---|---|---|
| Reduced tacrolimus N = 375 | Standard tacrolimus N = 495 | p Valueb | EC-MPS N = 589 | MMF N = 281 | p Valueb | |
| Follow-up (d) | 0.034 | |||||
| Mean (SD) | 410 (266) | 443 (289) | 415 (271) | 459 (296) | ||
| Median | 365 | 386 | 367 | 388 | ||
| Range | 10–1107 | 11–1094 | 10–1107 | 14–1094 | ||
| Recipient | ||||||
| Age (yr), mean (SD) | 50.6 (13.5) | 52.5 (13.4) | 0.039 | 52.4 (13.4) | 50.2 (13.5) | 0.025 |
| Male gender, n (%) | 246 (65.6) | 309 (62.4) | 370 (62.8) | 185 (65.8) | ||
| Race/ethnicity, n (%)c | <0.001d | |||||
| White | 236 (62.9) | 355 (71.7) | 400 (67.9) | 191 (68.0) | ||
| African American | 116 (30.9) | 92 (18.6) | 143 (24.3) | 65 (23.1) | ||
| Other | 28 (7.5) | 50 (10.1) | 50 (8.5) | 28 (10.0) | ||
| Previous renal transplant, n (%) | 34 (9.1) | 44 (8.9) | 54 (9.2) | 24 (8.5) | ||
| Pre-transplant dialysis, n (%) | 317 (84.5) | 391 (79.0) | 0.038 | 484 (82.2) | 224 (79.7) | |
| Reason for transplantation, n (%) | ||||||
| Hypertension/nephrosclerosis | 89 (23.7) | 110 (22.2) | 140 (23.8) | 59 (21.0) | ||
| Diabetes mellitus | 83 (22.1) | 119 (24.0) | 133 (22.6) | 69 (24.6) | ||
| Polycystic disease | 46 (12.3) | 54 (10.9) | 71 (12.1) | 29 (10.3) | ||
| Glomerulonephritis/glomerular disease | 52 (13.9) | 73 (14.8) | 93 (15.8) | 32 (11.4) | ||
| Other | 90 (24.0) | 114 (23.0) | 122 (20.7) | 82 (29.2) | ||
| Unknown | 15 (4.0) | 25 (5.1) | 30 (5.1) | 10 (3.6) | ||
| Peak panel-reactive antibody <30%, n/N,% | 274/329 (83.3) | 368/445 (82.7) | 433/523 (82.8) | 209/251 (83.3) | ||
| Delayed graft function, n/N (%) | 53/360 (14.7) | 78/485 (16.1) | 85/574 (14.8) | 46/271 (17.0) | ||
| Donor | ||||||
| Age (yr), mean (SD) | 42.2 (14.7) | 40.7 (14.6) | 41.3 (14.8) | 41.5 (12.3) | ||
| Age ≥60 yr, n (%) | 33 (8.9) | 47 (9.6) | 56 (9.6) | 24 (8.6) | ||
| Male gender, n (%) | 197 (52.5) | 244 (49.5) | 316 (53.7) | 125 (44.6) | 0.012 | |
| Type of donor, n/N (%) | 0.017d | |||||
| Deceased (heart beating) | 160/374 (42.8) | 223/494 (45.1) | 272/587 (46.3) | 111/281 (39.5) | ||
| Donation after cardiac death | 66/374 (17.6) | 51/494 (10.3) | 84/587 (14.3) | 33/281 (11.7) | ||
| Living related | 82/374 (21.9) | 117/494 (23.7) | 127/587 (21.6) | 72/281 (25.6) | ||
| Living unrelated | 66/374 (17.6) | 103/494 (20.9) | 104/587 (17.7) | 65/281 (23.1) | ||
| Expanded criteria donor, n/N (%) | 49/374 (13.1) | 56/492 (11.4) | 73/587 (12.4) | 32/279 (11.5) | ||
| Cold ischemia time (h), mean (SD) | 11.0 (9.9) | 10.3 (10.1) | 11.0 (9.9) | 9.8 (10.3) | ||
MPA, mycophenolic acid; EC-MPS, enteric-coated mycophenolate sodium; MMF, mycophenolate mofetil; SD, standard deviation.
All differences were non-significant unless stated otherwise. Significant p values (<0.05) are shown.
a
Within two wk post-transplant.
b
p Value is based on analysis of variance for continuous variables and Pearson's chi-square test for categorical variables.
c
Patients could be entered in more than one category.
d
p Value refers to a comparison across all categories.